Quality of Life and Voice Perception in Patients Laryngoctomized Phonatory Wearers

Sponsor
Regina Elena Cancer Institute (Other)
Overall Status
Recruiting
CT.gov ID
NCT06086119
Collaborator
San Giovanni Addolorata Hospital (Other), Azienda Policlinico Umberto I (Other)
31
1
36
0.9

Study Details

Study Description

Brief Summary

Prospective, multicenter observational study involving patients who will undergo total laryngectomy surgery and placement of phonatory prosthesis.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: to assess the voice perception of the patient undergoing phonatory prosthesis placement surgery by evaluating the optimal score (>30) in terms of VHI.

Study Design

Study Type:
Observational
Anticipated Enrollment :
31 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Quality of Life and Voice Perception in Patients Laryngoctomized Phonatory Wearers
Actual Study Start Date :
May 4, 2021
Actual Primary Completion Date :
Oct 15, 2022
Anticipated Study Completion Date :
May 4, 2024

Arms and Interventions

Arm Intervention/Treatment
Patients who will be subjected to total laryngectomy and placement of voice prosthesis

Prospective, multicenter observational study involving patients who will be subjected to total laryngectomy and placement of voice prosthesis.Evaluate the patient's quality of life and voice perception underwent surgery for the placement of a voice prosthesis, through the administration of validated quality of life questionnaires: EORTC QLQ - H&N35; EORTC QLQ -C30, V-RQOL, VHI, SECEL3,4

Diagnostic Test: to assess the voice perception of the patient undergoing phonatory prosthesis placement surgery by evaluating the optimal score (>30) in terms of VHI.
Prospective, multicenter observational study involving patients who will undergo total laryngectomy surgery and placement of phonatory prosthesis

Outcome Measures

Primary Outcome Measures

  1. evaluate the patient's quality of life and voice perception underwent surgery for the placement of a voice prosthesis [Enlistment period: 2 years Total duration of the study: 36 months]

    Evaluate the perception of the voice of the patient undergoing surgery of voice prosthesis positioning, evaluating the optimal score (>30) in terms of VHI. To calculate the sample size we based our estimate on the percentage of patients not undergoing voice prosthesis with a VHI score greater than 30 (Good Score). Such percentage is approximately 35%, a figure reported in the literature. Assuming a difference of 25% in terms of percentage of patients undergoing voice prosthesis who have a VHI score greater than 30 (60%) to ensure a power (1-β) equal to 80% and an α error of 5%, it will be necessary to enlist a total of 31 patients with the required requirements. Descriptive statistics will be calculated for all variables of interest. The associations will come evaluated using Fisher's exact test. Differences between subgroups will be assessed using the Mann-Whitney U test. All statistical analyzes were conducted using SPSS statistical software (version 21.0)

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Inclusion Criteria:
  • Patients who will undergo laryngeal demolition surgery, total laryngectomy, who agree to phonatory prosthesis placement

  • Patients who have undergone previous total laryngectomy surgery and intend to undergo placement of phonatory prosthesis.

  • Age > 18 years

  • Written informed consent

Exclusion Criteria:
  • Patients who have not undergone demolitive surgical treatment by total laryngectomy or who do not accept the placement of phonatory prosthesis.

  • Patients who are unable to complete questionnaires/follow the rehabilitation pathway

Contacts and Locations

Locations

Site City State Country Postal Code
1 "Regina Elena" National Cancer Institute Rome Italy 00144

Sponsors and Collaborators

  • Regina Elena Cancer Institute
  • San Giovanni Addolorata Hospital
  • Azienda Policlinico Umberto I

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Regina Elena Cancer Institute
ClinicalTrials.gov Identifier:
NCT06086119
Other Study ID Numbers:
  • RS1497/21
First Posted:
Oct 17, 2023
Last Update Posted:
Oct 17, 2023
Last Verified:
Jun 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 17, 2023